Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Avatar Builder  |  Contact Info  |  Update Email  |  Update Password  |  Leaderboards  |  Manage Favourite  |  Reputation  |  Reputation History  |  Subscriptions  |  Payment Info  |  Invoices  |  Favourites

Bullboard Post History

by Noteable

T.ONC

RE:How does Accelerated Approval work

ONCY is seeking accelerated approval for its lead cancer therapy, pelareorep,...

October 28, 2024

T.ONC

RE:RE:RE:Development of PD-L1 Antibody Drug Conjugates (ADC)

With all of these positive developments ONCY appears to be fast approaching a...

October 27, 2024

T.ONC

RE:RE:Development of PD-L1 Antibody Drug Conjugates (ADC)

This is exciting for good reason in the world of cancer immunotherapy. ONCY&...

October 27, 2024

T.ONC

RE:Development of PD-L1 Antibody Drug Conjugates (ADC)

As previously posted, ONCY's pelareorep is capable of synergistically...

October 27, 2024

T.ONC

Development of PD-L1 Antibody Drug Conjugates (ADC)

In 2022 research teams had chosen Atezolizumab, an anti-PD-L1 mAb to be...

October 27, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy

On September 13, 2024 Pfizer announced that "Pfizer's PD-L1 Antibody...

October 27, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy

Like yourself JohnnyYeg, I think that Matt has focused his attention on...

October 27, 2024

T.ONC

RE:RE:Liver Cancer

For the Reo013 (pelareorep) 'repeated doses' trial: - European...

October 26, 2024

T.ONC

RE:Liver Cancer

The high mortality ratio of liver cancer made it fourth leading cause of...

October 26, 2024

T.ONC

RE:RE:RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy

Looks like Matt Coffey has been active in developing a new cancer indication...

October 26, 2024

T.ONC

RE:RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy

October 01, 2024 - TOMAS PUEYO of "Uncharted Territories" asks...

October 26, 2024

T.ONC

RE:RE:RE:RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy

Pfizer on the use of Immune Checkpoint Inhibitors, CAR-T therapy, and...

October 26, 2024

T.ONC

RE:RE:RE:CellPress: Emerging Field of OV Based Cancer Immunotherapy

The oncolytic virus reovirus (pelareorep) has demonstrated that it can...

October 25, 2024

T.ONC

RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

October 21, 2024 - Sanofi has officially struck a deal to sell a 50...

October 21, 2024

T.ONC

RE:RE: mBC researcher self-treated with OV now recurrent free

This unconventional case finding further confirms ONCY's Phase 2 Bracelet...

October 19, 2024

T.ONC

RE: mBC researcher self-treated with OV now recurrent free

The August 2024 reporting concluded that :  'Although an isolated...

October 19, 2024

T.ONC

mBC researcher self-treated with OV now recurrent free

https://www.researchgate.net/publication/383452102_An_Unconventional_Case...

October 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

In 2023 Dominic Barton testified before one of Canada's House of Commons...

October 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

Should read: The posts are all relevant to ONCY, in particualr the 13 years...

October 19, 2024

T.ONC

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

The posts are all relevant to ONCY, the 13 years of market exclusivity at...

October 19, 2024

Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next

Featured Company

Forsys Metals Corp

Forsys Metals Corp T.FSY

Forsys Metals Corp. is a Canada-based uranium developer. The Company is engaged in the acquisition, exploration and ... view more »